Overview

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Status:
COMPLETED
Trial end date:
2021-06-03
Target enrollment:
Participant gender:
Summary
Phase II study of Durvalumab+/- Tremelimumab in patients with recurred metastatic head and neck squamous cell carcinoma
Phase:
PHASE2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Korean Cancer Study Group
Treatments:
durvalumab
tremelimumab